I agree that there is still a lot we can do to combat fungal disease.

However, your points 1, 2, and 4 unfortunately don't apply well to anti-fungals.

* "There is limited evidence that farming use of [anti-fungals] is what drives resistance in clinical cases."

Certainly not the case with respect to azoles:

-- Rhodes J, et al. Population genomics confirms acquisition of drug-resistant Aspergillus fumigatus infection by humans from the environment. Nat Microbiol. 2022 May;7(5):663-674. doi: 10.1038/s41564-022-01091-2. Epub 2022 Apr 25. Erratum in: Nat Microbiol. 2022 Nov;7(11):1944. doi: 10.1038/s41564-022-01160-6. PMID: 35469019; PMCID: PMC9064804. https://pubmed.ncbi.nlm.nih.gov/35469019/

-- Celia-Sanchez BN, Mangum B, Gómez Londoño LF, Wang C, Shuman B, Brewer MT, Momany M. Pan-azole- and multi-fungicide-resistant Aspergillus fumigatus is widespread in the United States. Appl Environ Microbiol. 2024 Apr 17;90(4):e0178223. doi: 10.1128/aem.01782-23. Epub 2024 Apr 1. PMID: 38557086; PMCID: PMC11022549.

-- Impact of the use of azole fungicides, other than as human medicines, on the development of azole‐resistant Aspergillus spp. https://www.efsa.europa.eu/en/efsajournal/pub/9200

"* There is no reason to believe we've hit a wall and can't invent more antibiotics in the future. "

-- There are very few anti-fungals, because fungi, being eukaryotes, have cell biology so close to ours. The "big three" are 1) azoles (lots of resistance; see above); 2) echinocandins; and 3) amphotericin B (highly toxic to the host)

-- One bright spot is a new antifungal published a few weeks ago in Nature, called Mandimycin: https://www.nature.com/articles/d41586-025-00801-0

* "There are still some antimicrobial treatment techniques we haven't put a lot of resources in. Like, bacteriophage treatments, or cycling antibiotics."

-- Bacteriophage don't work on fungi. Some degree of cycling and combination anti-fungal treatment are already in use.